Enanta (ENTA) Pharmaceuticals announced that the first participant has been dosed in a Phase 1 clinical trial of EDP-978, an oral, once-daily KIT inhibitor in development for urticaria and other mast cell-driven diseases. The Phase 1 single-ascending dose, SAD, and multiple-ascending dose, MAD, clinical trial will evaluate the safety, tolerability, pharmacokinetics, PK, and pharmacodynamics, PD, of EDP-978 in healthy adult volunteers.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA:
- Enanta Advances Federal Circuit Appeal in Paxlovid Patent Case
- Enanta initiated with a Buy at Rodman & Renshaw
- Enanta’s New RSV Trial in Infants: What Investors Should Watch in ENTA
- Enanta Shareholders Approve Board Elections and Equity Plan
- Enanta Pharmaceuticals: RSV Monoclonal Headwinds Turn Tailwind for Zelicapavir Treatment Opportunity